Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Provided By PR Newswire
Last update: Nov 11, 2025
Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors
Read more at prnewswire.com
